Zanamivir Treatment Is Equally Effective for Both Influenza A and Influenza B

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B

“…9 In this study, duration of fever from the first inhalation of zanamivir was almost equal (5e10 years) or slightly longer (>10 years or all ages) for patients with influenza B than for patients with influenza A in the 2006e2007 season. There was no significant difference in the duration of fever from the onset or the percentage of patients afebrile at 24 h or 48 h between influenza A and influenza B in all ages.…”

“…4 The effectiveness of zanamivir, another neuraminidase inhibitor, has been reported, 5e8 but it has not been compared fully between influenza A and influenza B, except for our recent preliminary report on a small number of patients. 9 In the preliminary study, we reported that zanamivir was effective for influenza B as well as influenza A by analyzing the percentage of patients afebrile at 24 and 48 h after the start of therapy. However, the effectiveness of zanamivir and oseltamivir for influenza B has not been compared with a large number of patients, including our previous studies.…”

Clinical Effectiveness of Oseltamivir and Zanamivir for Treatment of Influenza A Virus Subtype H1N1 with the H274Y Mutation: A Japanese, Multicenter Study of the 2007–2008 and 2008–2009 Influenza Seasons

“…The time from the initial administration of oseltamivir or zanamivir to the resolution of fever and the duration of fever between the onset of symptoms and resolution were calculated automatically in the SQL database [5,7]. The percentage of patients who were febrile at 48 h and 72 h after the first dose of oseltamivir or zanamivir was calculated [11].…”

A change in the effectiveness of amantadine for the treatment of influenza over the 2003–2004, 2004–2005, and 2005–2006 influenza seasons in Japan

“…24 We also recently reported that zanamivir, another neuraminidase inhibitor, was equally effective for both infl uenza A and B. 25 Consideration of viral resistance and the shedding periods of infl uenza A and infl uenza B are important when selecting a neuraminidase inhibitor for use as an anti-infl uenza drug.…”